Serotonin Receptor HTR2A Genotyping
HTR2A and HTR2C genes encode receptors for serotonin, a neuron transmitter that plays an essential role in the human brain. The gene is located on chromosome 13 (13q14-q21). Mutations in the HTR genes are associated with schizophrenia and obsessive-compulsive disorder, and also potentially affect many antidepressant medications, such as citalopram in patients with major depressive disorder (MDD). Patients with major depressive disorder often suffer from unsuccessful treatment with specific antidepressant and antipsychotic medications. Genetic-based drug guidance becomes possible from recent discoveries in pharmacogenetics. More effective selection of antidepressants has been guided by genotyping genes encoding several cytochrome P450 enzymes, the serotonin transporter and the serotonin receptors.
Several genetic variations (polymorphisms) in the HTR2A gene have been found to affect drug responses or adversary drug reactions. Most common tested variation and phenotypes are as follow:
The rs6313 polymorphism (102C>T) has been found to associated with weight gain for patients treated with olanzapine. AA genotype may leads to higher risk of weight gain than the GG genotype for schizophrenia patients treated with olanzapine.
The rs7997012 (IVS2+5453A->G) polymorphism has been shown to affect the treatment of antidepressants, and citalopram in various populations. Patients with AA genotype are more likely to benefit from citalopram or antidepressants treatment.
The rs6311 (-510G>A) polymorphism is associated with poorer response to risperidone in children with autism and decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia.
For the rs6314 (1354C->T) polymorphism, the CC genotype is associated with better response to clozapine.
- Determining therapeutic strategy for antidepressant and antipsychotic drugs
- Monitor and manage citalopram and clozapine therapy
- Risk management for Weight gain of those patients receiving olanzapine
- The rs6313 polymorphism (102C>T) has been found to be associated with weight gain for patients treated with olanzapine. AA genotype may leads to higher risk of weight gain than the GG genotype for schizophrenia patients treated with olanzapine.
- The rs7997012 (IVS2+5453A->G) polymorphism has been shown to affect the treatment of antidepressants, and citalopram in various populations. Patients with AA genotype are more likely to benefit from citalopram or antidepressants treatment.
- The rs6311 (-510G>A) polymorphism is associated with poorer response to risperidone in children with autism and decreased risk of tardive dyskinesia when treated with antipsychotics in people with schizophrenia.
- The rs6314 (1354C->T) polymorphism, the CC genotype is associated with better response to clozapine.
Wild type
Blood
Whole blood collected in lavender top tube (EDTA) or any anticoagulant collection devices. Buccal swab is also used.
Stability
- Ambient: 5 days
- Refrigerated: 7 days
- Mol Psychiatry. 2010 May;15(5):473-500. [PMID: 18982004]
- Mol Psychiatry. 2010 May;15(5):445. [PMID: 20424621]
- Lancet. 2000;355(9215):1615-1616. [PMID: 10821369]
- J Clin Psychiatry. 2008 Sep;69(9):1416-22. [PMID: 19193342]
- J Hum Genet 2006;78:804-814. [PMID: 16642436]
- Eur Neuropsychopharmacol. 2010 Jan;20(1):65-8. [PMID: 19758789]